|
Independent and Combined Association of Overweight and Obesity and Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) with 10-Year Atherosclerotic Cardiovascular Disease Risk in Patients with Type 2 Diabetes
|
N Naderi    , M Fardesharifi , D Allahverdi , H Poustchi , Z Yari * |
| Assistant professor, Department of Nutrition Research, National Nutrition and Food Technology Research Institute and Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran , Zahrayari_nut@yahoo.com |
|
|
Abstract: (45 Views) |
Background and Objectives: Type 2 diabetes mellitus (T2DM), obesity, and metabolic dysfunction–associated steatotic liver disease (MASLD) are associated with an elevated risk of atherosclerotic cardiovascular disease (ASCVD). However, the independent and combined effects of obesity and MASLD on the 10-year ASCVD risk among individuals with T2DM remain poorly defined.
Materials & Methods: In this cross-sectional study, 200 patients with T2DM attending the endocrinology clinic at Dr. Shariati Hospital, Tehran, were enrolled. Based on Fibroscan results, patients were classified into MASLD and non-MASLD groups. Body mass index (BMI) and 10-year ASCVD risk were calculated using the ACC/AHA Pooled Cohort Equations. Multivariate logistic regression was performed, adjusting for age, sex, and diabetes duration.
Results: Overall, 66.5% of participants were diagnosed with MASLD. Compared to those without MASLD, patients with MASLD had significantly higher mean BMI (30.07 vs. 26.17; P<0.001), total and LDL cholesterol, and 10-year ASCVD risk scores (8.29% vs. 5.96%; P=0.023). In the adjusted model, both obesity (adjusted odds ratio [aOR] = 3.52; 95% CI: 1.38–8.95) and MASLD (aOR = 3.58; 95% CI: 1.71–7.49) were independently associated with high ASCVD risk
(≥ 7.5%). In addition, being overweight and obese concurrent with having MASLD was associated with a 3.11-fold and 4.44-fold increase in the risk of ASCVD, respectively.
Conclusion: Both MASLD and obesity independently and synergistically increase the 10-year ASCVD risk in patients with T2DM. These findings highlight the importance of concurrent identification and management of MASLD and obesity in the cardiometabolic care of diabetic patients. |
|
| Keywords: Type two diabetes mellitus, MASLD, obesity, 10-year ASCVD risk, cardiovascular disease |
|
|
Full-Text [PDF 865 kb]
(16 Downloads)
|
Article type: Research |
Subject:
nutrition
Received: 2025/06/10 | Accepted: 2025/08/5 | Published: 2026/05/18
|
|
|
|
|
|
|
| References |
1. Alfieri CM, Molinari P, Cinque F, Vettoretti S, Cespiati A, Bignamini D, et al. What Not to Overlook in the Management of Patients with Type 2 Diabetes Mellitus: The Nephrological and Hepatological Perspectives. International Journal of Molecular Sciences. 25.14 (2024): 7728. [ DOI:10.3390/ijms25147728] 2. Basevi V. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2011;34:S62 - S9. [ DOI:10.2337/dc11-S062] 3. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology. 2018;14(2):88-98. [ DOI:10.1038/nrendo.2017.151] 4. Qiao T, Luo T, Pei H, Yimingniyazi B, Aili D, Aimudula A, et al. Association between abdominal obesity indices and risk of cardiovascular events in Chinese populations with type 2 diabetes: a prospective cohort study. Cardiovascular Diabetology. 2022 Nov 1;21(1):225. [ DOI:10.1186/s12933-022-01670-x] 5. Khawaja T, Nied M, Wilgor A, Neeland IJ. Impact of Visceral and Hepatic Fat on Cardiometabolic Health. Current Cardiology Reports. 2024;26:1297 - 307. [ DOI:10.1007/s11886-024-02127-1] 6. Oh R, Kim G, Lee K-n, Cho SH, Kim JY, Kim S, et al. Metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: risk of heart failure. Cardiovascular Diabetology. 2024 Nov 1;23(1):391. [ DOI:10.1186/s12933-024-02489-4] 7. Roshanravan N, Tutunchi H, Parvizi R, Bastani S, Asghari Jafarabadi M, Faramarzi E, et al. Risk factors for atherosclerotic cardiovascular disease (ASCVD) in healthcare professionals of Azar Cohort Study: A cross-sectional Study. Health Promot Perspect. 2024;14(2):161-7. [ DOI:10.34172/hpp.42568] 8. Michalopoulou E, Thymis J, Lampsas S, Pavlidis G, Katogiannis K, Vlachomitros D, et al. The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment. Journal of Clinical Medicine. 2025 Jan 10;14(2):428. [ DOI:10.3390/jcm14020428] 9. Ganakumar V, Halebidu T, Goroshi M, Ghatnatti V. Diagnosis and Management of MASLD: An Metabolic Perspective of a Multisystem Disease. International Journal of Clinical Metabolism and Diabetes. 2024;1:45 - 57. [ DOI:10.1177/30502071231220779] 10. Platek AE, Szymańska A. Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor. Clinical and Experimental Hepatology. 2023;9:187 - 92. [ DOI:10.5114/ceh.2023.130744] 11. Eskridge W, Cryer DR, Schattenberg JM, Gastaldelli A, Malhi H, Allen AM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective. J Clin Med. 2023;12(19). [ DOI:10.3390/jcm12196216] 12. Ebeid A, Mokhtar F, Martinez-Lebron V, Park S, Degann S, Payano J, et al. Use of noninvasive fibrosis calculators in an urban diabetes center suggests a large burden of undetected advanced liver disease. BMC Endocrine Disorders. 2025 Feb 27;25(1):53. [ DOI:10.1186/s12902-025-01881-9] 13. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589-600. [ DOI:10.1016/j.jhep.2016.05.013] 14. Moon JH, Jeong S, Jang H, Koo BK, Kim W. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study. EClinicalMedicine. 2023;65:102292. [ DOI:10.1016/j.eclinm.2023.102292] 15. Nagao H, Kashine S, Nishizawa H, Okada T, Kimura T, Hirata A, et al. Vascular complications and changes in body mass index in Japanese type 2 diabetic patients with abdominal obesity. Cardiovascular Diabetology. 2013 Jun 18;12(1):88. [ DOI:10.1186/1475-2840-12-88] 16. Mikolasevic I, Milić S, Turk Wensveen T, Grgic IH, Jakopčić I, Štimac D, et al. Nonalcoholic fatty liver disease - A multisystem disease? World Journal of Gastroenterology. 2016;22:9488 - 505. [ DOI:10.3748/wjg.v22.i43.9488] 17. Gao X, Chen T, Zhou F, Sun Y, Zhang J, Li X, et al. The association between different insulin resistance surrogates and all-cause mortality and cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease. Cardiovascular Diabetology. 2025 May 9;24(1):200. [ DOI:10.1186/s12933-025-02758-w] 18. Salavatizadeh M, Soltanieh S, Ataei Kachouei A, Abdollahi Fallahi Z, Kord-Varkaneh H, Poustchi H, et al. Association between dietary glycemic index and non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Frontiers in Endocrinology. 2023 Aug 22;14:1228072. [ DOI:10.3389/fendo.2023.1228072] 19. Zhao Y, Qie R, Han M, Huang S, Wu X, Zhang Y, et al. Association of BMI with cardiovascular disease incidence and mortality in patients with type 2 diabetes mellitus: A systematic review and dose-response meta-analysis of cohort studies. Nutr Metab Cardiovasc Dis. 2021;31(7):1976-84. [ DOI:10.1016/j.numecd.2021.03.003] 20. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21):e984-e1010. [ DOI:10.1161/CIR.0000000000000973] 21. Yanai H, Adachi H, Hakoshima M, Iida S, Katsuyama H. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. Int J Mol Sci. 2023 Oct 23;24(20):15473. [ DOI:10.3390/ijms242015473] 22. Luo W, Zhang J, Xu D, Zhou Y, Qu Z, Yang Q, et al. Low carbohydrate ketogenic diets reduce cardiovascular risk factor levels in obese or overweight patients with T2DM: A meta-analysis of randomized controlled trials. Front Nutr. 2022 Dec 13;9:1092031. [ DOI:10.3389/fnut.2022.1092031] 23. Lichtenstein AH, Appel LJ, Vadiveloo M, Hu FB, Kris-Etherton PM, Rebholz CM, et al. 2021 dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2021;144(23):e472-e87. [ DOI:10.1161/CIR.0000000000001031] 24. Mellemkjær A, Kjær MB, Haldrup D, Grønbæk H, Thomsen KL. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;122:28-34. [ DOI:10.1016/j.ejim.2023.11.012] 25. Driessen S, Francque SM, Anker SD, Castro Cabezas M, Grobbee DE, Tushuizen ME, et al. Metabolic dysfunction associated steatotic liver disease and the heart. Hepatology. 2023 Dec 25:10-97. 26. Ferenc K, Jarmakiewicz-Czaja S, Sokal-Dembowska A, Stasik K, Filip R. Common Denominator of MASLD and Some Non-Communicable Diseases. Current Issues in Molecular Biology. 2024;46:6690 - 709. [ DOI:10.3390/cimb46070399] 27. Cho EEL, Ang CZ, Quek J, Fu CE, Lim LKE, Heng ZEQ, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138-48. [ DOI:10.1136/gutjnl-2023-330110] 28. Chaudhary MYN, Jawwad M, Ismail M, Chaudhary MHN, Asghar A, Ahmed SA, et al. S2037 Comparative Diagnostic Accuracy of Fibrotouch and Fibroscan in Assessing Liver Fibrosis: A Systematic Review and Meta-Analysis. Official journal of the American College of Gastroenterology | ACG. 2024;119(10S). [ DOI:10.14309/01.ajg.0001037516.46225.38] 29. Moghaddam MB, Aghdam FB, Jafarabadi MA, Allahverdipour H, Nikookheslat SD, Safarpour S. The Iranian Version of International Physical Activity Questionnaire (IPAQ) in Iran: content and construct validity, factor structure, internal consistency and stability. World Appl Sci J. 2012;18(8):1073-80. 30. Zibaeenejad F, Mohammadi SS, Sayadi M, Safari F, Zibaeenezhad MJ. Ten-year atherosclerosis cardiovascular disease (ASCVD) risk score and its components among an Iranian population: a cohort-based cross-sectional study. BMC Cardiovasc Disord. 2022;22(1):162. [ DOI:10.1186/s12872-022-02601-0] 31. Khan HW, Imran M, Khan S, Athar MH, Tahir HB, Ali I. 10-Year Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score Calculation in Out-Patient Department. Pakistan Armed Forces Medical Journal. 2024;74(5):1255-9. [ DOI:10.51253/pafmj.v74i5.6958] 32. Zhou YY, Zhou XD, Wu SJ, Hu XQ, Tang B, Poucke SV, et al. Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis. Eur J Gastroenterol Hepatol. 2018;30(6):631-6. [ DOI:10.1097/MEG.0000000000001075] 33. Riley DR, Hydes T, Hernadez G, Zhao SS, Alam U, Cuthbertson DJ. The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes. Liver Int. 2024;44(10):2538-50. [ DOI:10.1111/liv.16016] 34. Lv Q, Zhao H. The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis. Ann Med. 2024;56(1):2306192. [ DOI:10.1080/07853890.2024.2306192] 35. Salavatizadeh M, Soltanieh S, Poustchi H, Yari Z, Shabanpur M, Mansour A, et al. Dietary total antioxidant capacity is inversely associated with the odds of non-alcoholic fatty liver disease in people with type-2 diabetes. Frontiers in Nutrition. 2022 Nov 3;9:1037851. [ DOI:10.3389/fnut.2022.1037851] 36. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45(10):1929-34. [ DOI:10.1023/A:1005661516165] 37. Matsubayashi Y, Fujihara K, Khin L, Ferreira ED, Takabayashi S, Yamashita Y, et al. Association of changes in the type 2 diabetes and MASLD/related SLD status with risk of developing cardiovascular disease. Diabetes Obes Metab. 2025;27(4):2035-43. [ DOI:10.1111/dom.16196] 38. Muzurović EM, Peng CCH, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors. Hypertension. 2022;79:1319 - 26. [ DOI:10.1161/HYPERTENSIONAHA.122.17982] 39. Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. Bmj. 2019;367:l5367. [ DOI:10.1136/bmj.l5367] 40. Cernea S, Onisor DM, Roiban AL, Benedek T, Raț N. Metabolic dysfunction-associated steatotic liver disease-associated fibrosis and cardiac dysfunction in patients with type 2 diabetes. World Journal of Cardiology. 2024;16:580 - 94. [ DOI:10.4330/wjc.v16.i10.580] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Naderi N, fardesharifi M, Allahverdi D, Poustchi H, Yari Z. Independent and Combined Association of Overweight and Obesity and Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) with 10-Year Atherosclerotic Cardiovascular Disease Risk in Patients with Type 2 Diabetes. Iranian J Nutr Sci Food Technol 2026; 21 (1) :23-34 URL: http://nsft.sbmu.ac.ir/article-1-4010-en.html
|
